Aurora Cannabis (ACB) Net Income towards Common Stockholders (2017 - 2026)

Aurora Cannabis (ACB) posted quarterly Net Income towards Common Stockholders of $5.6 million for Q1 2026, down 63.46% year-on-year from $15.3 million in Q1 2025, and down 52.34% on a QoQ basis from $11.7 million in Q4 2025.

Aurora Cannabis (ACB) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends

Aurora Cannabis (ACB) has reported Net Income towards Common Stockholders for 10 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 63.46% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $802.1 million (down 35.01% YoY) and the FY2026 annual result came in at -$42.4 million, down 110.4% from the prior year.
  • Net Income towards Common Stockholders declined to $5.6 million in Q1 2026 per ACB's latest filing, from $11.7 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for ACB reached as high as $860.2 million in Q1 2022 and fell as low as -$545.4 million in Q4 2022.
  • A 5-year average of $165.5 million and a median of $359.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 4195.43% — and 2025, when it soared 1023.24%.
  • Year by year, Net Income towards Common Stockholders stood at -$545.4 million in 2022, then soared by 169.56% to $379.4 million in 2023, then climbed by 8.11% to $410.1 million in 2024, then tumbled by 97.14% to $11.7 million in 2025, then tumbled by 52.34% to $5.6 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $5.6 million, $11.7 million, and $386.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 90.13 Bn 88.27 Bn - -
2 Teva Pharmaceutical Industries 35.98 Bn 32.24 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.59 Bn 30.65 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.55 Bn 23.49 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 23.08 Bn 20.93 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 21.48 Bn 21.48 Bn - -
7 Viatris 20.38 Bn 18.57 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.80 Bn 16.48 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.64 Bn 12.21 Bn 785.00 Mn 57.00 Mn
10 Aurora Cannabis 153.98 Mn 68.73 Mn 21.72 Mn 5.58 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 5.58 Mn
Dec 31, 2025 11.71 Mn
Sep 30, 2025 386.51 Mn
Jun 30, 2025 398.33 Mn
Mar 31, 2025 15.27 Mn
Dec 31, 2024 410.12 Mn
Sep 30, 2024 398.17 Mn
Jun 30, 2024 410.62 Mn
Mar 31, 2024 -1.65 Mn
Dec 31, 2023 379.35 Mn
Sep 30, 2023 375.79 Mn
Jun 30, 2023 354.16 Mn
Mar 31, 2023 359.55 Mn
Dec 31, 2022 -545.38 Mn
Sep 30, 2022 -515.60 Mn
Jun 30, 2022 -488.98 Mn
Mar 31, 2022 860.20 Mn
Dec 31, 2021 1.55 Bn
Sep 30, 2021 -12.00 Mn
Jun 30, 2021 -87.26 Mn